Replies to post #126044 on Biotech Values

[DewDiligence]

Re: Teva’s untruthfulness

…I think there are plenty of other examples and it might be interesting to compile the list.

Here’s a partial list:

#msg-54184212 Infamous “one month behind” comment re Lovenox approval
#msg-52989044 Bernstein (spoon-fed by Teva) says Teva close to Lovenox approval
#msg-59164333 Teva spins Jan 2011 deficiency letter as minor
#msg-56217639 Disingenuous comments on 3Q10 CC (transcript)
#msg-56186101 Disingenuous comments on 3Q10 CC: analysis (1)
#msg-56195372 Disingenuous comments on 3Q10 CC: analysis (2)
#msg-56200077 Disingenuous comments on 3Q10 CC: analysis (3)
#msg-56267201 Teva mischaracterizes the “junk” in Lovenox
#msg-58308206 Teva won’t say whether Lovenox sales are in EPS guidance
#msg-56181076 Teva says in “labeling discussions” on Lovenox (Nov 2009)

#msg-45378265 Bogus Copaxone arithmetic
#msg-54609550 LOL re rationale for low-volume Copaxone
#msg-58084633 Teva spins FDA rejection of low volume Copaxone as a positive

I could find more, but the above are probably sufficient for you to make your point about Teva’s lack of truthfulness.